Pharmacokinetics of teicoplanin upon multiple dose intravenous administration to normal healthy male volunteers

✍ Scribed by Gary A. Thompson; Jacquelyn A. Smithers; Michael T. Kenny; Jacqueline K. Dulworth; Henrik K. Kulmala; Lianng Yuh; Eric W. Lewis; Kelly K. Antony

• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: English
• Weight: 390 KB
• Volume: 13
• Category: Article
• ISSN: 0142-2782
• DOI: 10.1002/bdd.2510130307

✦ Synopsis

Abstract

Teicoplanin pharmacokinetics were investigated upon multiple dose intravenous administration of 6 and 12 mg kg^−1^ in 10 normal, healthy, male volunteers, using a two‐period, randomized, crossover design; six subjects completed both periods. On day 1, 6 or 12 mg kg^−1^ was administered every 12 h as a 30‐min constant rate intravenous infusion (two doses). Starting on day 2, the same dose (6 or 12 mg kg^−1^) was administered every 24 h for an additional 13 days. Blood and urine samples were collected over 21 days. Serum and urine were analyzed using a microbiological assay. Following a minimum of 3 weeks after completion of the first period, subjects were crossed over to the other dose. Following multiple dose intravenous administration of 6 and 12 mg kg^−1^, median pharmacokinetic parameters included: steady‐state volume of distribution of 1·4 and 1·21 kg^−1^; total clearance of 12·2 and 14·0 ml h^−1^ kg^−1^; renal clearance of 11·1 and 10·3 ml h^−1^ kg^−1^; and terminal disposition half‐life of 159 and 155 h, respectively. No statistically significant dose‐related difference was observed. In addition, a cross‐study comparison further supports dose proportionality of teicoplanin upon multiple dose intravenous administration of 3 to 12 mg kg^−1^.